These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 26342235)

  • 1. Expansion platform type II: testing a treatment strategy.
    Catenacci DV
    Lancet Oncol; 2015 Oct; 16(13):1276-8. PubMed ID: 26342235
    [No Abstract]   [Full Text] [Related]  

  • 2. Precision medicine: lessons learned from the SHIVA trial.
    Weiss GJ
    Lancet Oncol; 2015 Dec; 16(16):e580. PubMed ID: 26678199
    [No Abstract]   [Full Text] [Related]  

  • 3. Precision medicine: lessons learned from the SHIVA trial.
    Hahn AW; Martin MG
    Lancet Oncol; 2015 Dec; 16(16):e580-1. PubMed ID: 26678198
    [No Abstract]   [Full Text] [Related]  

  • 4. Precision medicine: lessons learned from the SHIVA trial.
    Tsimberidou AM; Kurzrock R
    Lancet Oncol; 2015 Dec; 16(16):e579-80. PubMed ID: 26678197
    [No Abstract]   [Full Text] [Related]  

  • 5. Precision medicine: lessons learned from the SHIVA trial - Authors' reply.
    Le Tourneau C; Belin L; Paoletti X; Bièche I; Kamal M
    Lancet Oncol; 2015 Dec; 16(16):e581-2. PubMed ID: 26678200
    [No Abstract]   [Full Text] [Related]  

  • 6. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Future of Precision Oncology for the Treatment of Solid Tumors.
    Klute KA
    Clin Pharmacol Ther; 2020 Sep; 108(3):416-418. PubMed ID: 31983061
    [No Abstract]   [Full Text] [Related]  

  • 8. Lack of access to targeted cancer therapy.
    Burki TK
    Lancet Oncol; 2015 Oct; 16(13):e482. PubMed ID: 26321211
    [No Abstract]   [Full Text] [Related]  

  • 9. Evidence-Based Development and Clinical Use of Precision Oncology Therapeutics.
    Comment LA; Ward AF; Schrock AB; Fabrizio D; Venstrom JM; Hegde PS; Alexander BM
    Clin Pharmacol Ther; 2020 Sep; 108(3):440-443. PubMed ID: 32744335
    [No Abstract]   [Full Text] [Related]  

  • 10. Personalising the treatment of prostate cancer.
    Gunjur A
    Lancet Oncol; 2015 Dec; 16(16):e592. PubMed ID: 26549591
    [No Abstract]   [Full Text] [Related]  

  • 11. Is Precision Medicine an Oxymoron?
    Eckhardt SG; Lieu C
    JAMA Oncol; 2019 Feb; 5(2):142-143. PubMed ID: 30419105
    [No Abstract]   [Full Text] [Related]  

  • 12. A precision, personalized approach to the management of bladder cancer.
    Apolo AB; Burger M
    Curr Opin Urol; 2015 Sep; 25(5):416-7. PubMed ID: 26153639
    [No Abstract]   [Full Text] [Related]  

  • 13. The evolving potential of companion diagnostics.
    Khoury JD
    Scand J Clin Lab Invest Suppl; 2016; 245():S22-5. PubMed ID: 27433788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Precision medicine beyond medical oncology: using molecular analysis to guide treatments of colorectal neoplasia.
    Molloy MP; Engel A
    Expert Rev Gastroenterol Hepatol; 2018 Dec; 12(12):1179-1181. PubMed ID: 30791786
    [No Abstract]   [Full Text] [Related]  

  • 15. Precision Medicine.
    Khatri VP; Petrelli NJ
    Surg Oncol Clin N Am; 2020 Jan; 29(1):xv-xvi. PubMed ID: 31757318
    [No Abstract]   [Full Text] [Related]  

  • 16. Maurie Markman on the Groundbreaking TAPUR Trial.
    Markman M
    Oncology (Williston Park); 2017 Mar; 31(3):158, 168. PubMed ID: 28299751
    [No Abstract]   [Full Text] [Related]  

  • 17. Giving Up on Precision Oncology? Not So Fast!
    Warner JL
    Clin Transl Sci; 2017 May; 10(3):128-129. PubMed ID: 28146309
    [No Abstract]   [Full Text] [Related]  

  • 18. National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer.
    Pal SK; Agarwal N; Boorjian SA; Hahn NM; Siefker-Radtke AO; Clark PE; Plimack ER
    J Clin Oncol; 2016 Sep; 34(27):3346-8. PubMed ID: 27458279
    [No Abstract]   [Full Text] [Related]  

  • 19. Paul Workman: Drugging the Cancer Genome.
    Trends Cancer; 2016 Oct; 2(10):544-548. PubMed ID: 27904887
    [No Abstract]   [Full Text] [Related]  

  • 20. Molecular profiling and commercial predication assays in ovarian cancer: still not ready for prime time?
    Kohn EC
    Am Soc Clin Oncol Educ Book; 2014; ():139-47. PubMed ID: 24857070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.